Fosphenytoin sodium

Base Information

• Chemical Name: Fosphenytoin sodium
• CAS No.: 92134-98-0
• Molecular Formula: C16H13N2Na2O6P
• Molecular Weight: 406.24
• Hs Code.: 2933290000
• Mol file: 92134-98-0.mol

Synonyms:2,4-Imidazolidinedione,5,5-diphenyl-3-[(phosphonooxy)methyl]-, disodium salt (9CI);ACC9653-010;CI 982;Cetebyx;Pro-Epanutin;

Chemical Property of Fosphenytoin sodium

Chemical Property:

• Appearance/Colour: White crystalline powder
• Melting Point: 220oC
• PSA: 131.64000
• LogP: 2.69190
• Storage Temp.: 2-8°C
• Solubility.: H2O: ≥15mg/mL

Purity/Quality:

99% ^*data from raw suppliers

Fosphenytoin sodium ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T
• Hazard Codes: T
• Statements: 45-61-22
• Safety Statements: 53-36/37-45

MSDS Files:

SDS file from LookChem

Useful:

• Uses: Fosphenytoin sodium is used in the treatment of epileptic seizures. PDE3 (phosphodiesterase 3) inhibitor Anti epileptic
• Therapeutic Function: Antiepileptic, Anticonvulsant
• Clinical Use: Control of status epilepticus Seizures associated with neurosurgery or head injury when oral phenytoin is not possible
• Drug interactions: Potentially hazardous interactions with other drugs Aminophylline and theophylline: concentration of both drugs reduced with aminophylline and theophylline. Analgesics: enhanced effect with NSAIDs; metabolism of methadone accelerated; possibly increases pethidine toxicity. Anthelmintics: concentration of albendazole and praziquantel reduced; concentration of fosphenytoin possibly increased by levamisole. Anti-arrhythmics: increased concentration with amiodarone; concentration of disopyramide and possibly dronedarone reduced - avoid with dronedarone. Antibacterials: level increased by clarithromycin, chloramphenicol, isoniazid, metronidazole, sulphonamides and trimethoprim (+ antifolate effect); concentration increased or decreased by ciprofloxacin; concentration of bedaquiline, doxycycline and telithromycin reduced - avoid with telithromycin; concentration reduced by rifamycins. Anticoagulants: increased metabolism of coumarins (reduced effect but also reports of enhancement); possibly reduced apixaban, dabigatran, edoxaban and rivaroxaban concentration - avoid with dabigatran. Antidepressants: antagonise anticonvulsant effect; concentration increased by fluoxetine and fluvoxamine and possibly sertraline; concentration of mianserin, mirtazapine and paroxetine and possibly tricyclics reduced; concentration reduced by St John’s wort - avoid. Antiepileptics: concentration of both drugs reduced with carbamazepine, concentration may also be increased by carbamazepine, eslicarbazepine, ethosuximide, oxcarbazepine, stripentol and topiramate; concentration of ethosuximide, active oxcarbazepine metabolite, retigabine, rufinamide (concentration of phenytoin possibly increased), topiramate and valproate possibly reduced; concentration of eslicarbazepine, ethosuximide, lamotrigine, perampanel, tiagabine and zonisamide reduced; concentration of phenobarbital oftenincreased; phenobarbital and valproate may alter concentration; concentration reduced by vigabatrin. Antifungals: concentration of ketoconazole, itraconazole, posaconazole, voriconazole and possibly isavuconazole and caspofungin reduced - avoid with isavuconazole and itraconazole, increase voriconazole dose and possibly caspofungin; levels increased by fluconazole, miconazole and voriconazole - consider reducing fosphenytoin dose. Antimalarials: avoid with piperaquine with artenimol, mefloquine and pyrimethamine - antagonise anticonvulsant effect; increased antifolate effect with pyrimethamine. Antipsychotics: antagonise anticonvulsant effect; possibly reduced aripiprazole concentration - increase aripiprazole dose; metabolism of clozapine, haloperidol, quetiapine and sertindole increased; concentration increased or decreased with chlorpromazine; possibly reduces lurasidone concentration - avoid. Antivirals: possibly reduced concentration of abacavir, boceprevir, daclatasvir, darunavir, dasabuvir, dolutegravir, indinavir, lopinavir, ombitasvir, paritaprevir, ritonavir, saquinavir and simeprevir - avoid with boceprevir, daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir; rilpivirine reduced - avoid; concentration possibly increased by indinavir and ritonavir; concentration increased or decreased with zidovudine; avoid with elvitegravir, etravirine and telaprevir. Apremilast: concentration of apremilast reduced - avoid. Calcium-channel blockers: levels increased by diltiazem; concentration of diltiazem, felodipine, isradipine, nimodipine and verapamil reduced; avoid with isradipine and nimodipine. Cannabis extract: concentration possibly reduced by phenytoin - avoid. Ciclosporin: reduced ciclosporin levels. Cobicistat: concentration of cobicistat possibly reduced. Corticosteroids: metabolism accelerated (effect reduced). Cytotoxics: metabolism possibly inhibited by fluorouracil; increased antifolate effect with methotrexate; reduced fosphenytoin absorption; concentration of busulfan, cabozantinib, ceritinib, eribulin, etoposide and imatinib reduced - avoid with cabozantib, ceritinib and imatinib; concentration possibly reduced by bosutinib, cisplatin ibrutinib and idelalisib - avoid with ibrutinib and idelalisib; possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of crizotinib - avoid; avoid with cabazitaxel, gefitinib, lapatinib, olaparib, panobinostat, vemurafenib and vismodegib; concentration of irinotecan and its active metabolite reduced. Dexrazoxane: absorption of fosphenytoin possibly reduced. Disulfiram: metabolism of fosphenytoin inhibited. Diuretics: concentration increased by acetazolamide; concentration of eplerenone reduced - avoid; increased risk of osteomalacia with carbonic anhydrses inhibitors; antagonises effect of furosemide. Guanfacine: concentration of guanfacine possibly reduced - increase dose of guanfacine. Hormone antagonists: possibly reduced concentration of abiraterone - avoid; metabolism of toremifene accelerated. Ivacaftor: concentration of ivacaftor possibly reduced - avoid. Muscle relaxants: long-term use of phenytoin reduces effects of non-depolarising muscle relaxants, but acute use may enhance effects. Oestrogens and progestogens: metabolism increased (reduced contraceptive effect). Orlistat: possibly increased risk of convulsions. Sulfinpyrazone: concentration increased by sulfinpyrazone. Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption reduced by sucralfate; enhanced effect with esomeprazole and omeprazole. Ulipristal: contraceptive effect possibly reduced - avoid.